Status:
UNKNOWN
Modified antioxIdants Bacteria for Gut Inflammation
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Centre National de la Recherche Scientifique, France
Conditions:
Chronic Inflammatory Small Bowel Disease
Eligibility:
All Genders
18+ years
Brief Summary
Patients with IBD experience complex therapeutic pathways. The development of new treatments, more effective and free of side effects, is a therapeutic need. However, such therapeutic innovations can ...
Detailed Description
Patients with IBD experience complex treatment pathways. Therapeutic innovations are necessary but can only be effective if they are accepted by the target populations. It is therefore a question of ...
Eligibility Criteria
Inclusion
- Patients with chronic inflammatory bowel diseases.
- Patients over 18 years old.
- Not opposed to participating in the study. - Patients whose diagnosis of IBD was made more than 6 months ago
Exclusion
- patients with cognitive disorders,
- patients who cannot read and understand French
Key Trial Info
Start Date :
February 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06189599
Start Date
February 1 2024
End Date
June 1 2024
Last Update
January 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de Gastroentérologie en Nutrition - Hôpital St Antoine
Paris, France, 75012